NM-136 / 9 Meters Biopharma - LARVOL DELTA

Efficacy, safety, and treatment durability of intravenous immunoglobulin in autoimmune blistering diseases (EADV 2023) - "IVIg has no major influence on the normal immune system, which makes its utilization for patients with AIBDs reasonable. Table 1** Demographic data, efficacy, and treatment durability of intravenous immunoglobulin in patients with bullous diseases Pemphigus#Bullous pemphigoid Mucous membrane pemphigoid Epidermolysis bullousa IVIg RTX+IVIg IVIg RTX+IVIg Patients 410 90 70 12 Clinical response, n (%) Yes 290 (90.9%) 61 (100%) 33 (80.5%) No 29 (9.1%) 0 (0.0%) 8 (19.5%) NM 91 29 29 Time to clinical response, m Mean 1.9 2.6 2.8 Range 0.3-7.5 0.4-6 2-4 NM 236 33 52 Clinical remission, n (%) Yes 227 (82.8%) 78 (86.7 %) 22 (88.0%) No 47 (17.2%) 12 (13.3%) 3 (12.0%) NM 136 0 45 Treatment durability Relapse, n (%) 41 (44.6%) 22 (40.8%) 10 (52.6%) Follow-up, m 37.2 67.8 22.7 NM 312 27 50 IVIg, intravenous immunoglobulin; RTX, rituximab; NM, not mentioned."

Clinical • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Pain